Summary.-Sera from 57 patients with malignant melanoma and 39 control patients were tested by immunofluorescence techniques against 6 melanoma cell lines. Thirty-two per cent of tests with sera from melanoma patients showed fluorescence with these cell lines whereas only 1700 of tests with control sera were positive. Reactions occurred in 210o of tests with sera from patients with primary melanoma compared with 4000 with secondary melanomata and 5400 with " cured " melanomata. The cell lines varied in antigenicity but this did not correlate with either pigmentation or length of time in culture. The cell lines which were most reactive with sera from melanoma patients were also most reactive with control sera.
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MALIGNANT melanoma has long been considered to be one of the more immunogenic human tumours. Studies bv Lewis (1967) , and subsequently by a number of workers using immunofluorescence techniques, seem to have substantiated that view by demonstrating antibody to melanoma cells in the serum of melanoma patients (Morton et al., 1968; Oettgen et al., 1968; Muna, Marcus and Scott, 1969; Lewis et al., 1969; Rohmsdahl and Cox, 1970) .
Four of these 5 groups of workers described antibody to Clark's classification (1967) showed that no serum from anv patient whose tumour was restricted to the epidermis or upper dermis (stage 1 or 2) reacted with any of the melanoma cell lines (Table IV) . Sixteen secondary sera were tested fully and there were a total of 36 reactions. IMl27 and MM182 were reacted 8 times, MM170 7 times, MM96 6 times, 1Ml38 4 times and MI181 3 times. These results are an indication of the diversity of reactions found.
DISCUSSION
This report describes a much lower incidence of antibody to melanoma than that found by most other authors using immunofluorescent techniques. However, the findings are in accordance with those of Nairn et al. (1972) , who have dealt in detail with the possible reasons for these discrepancies. Although early reports tended to agree as to the proportion of positive sera, the techniques and methods of assessment differed. For instance, Morton et al. (1968) described both nuclear and cytoplasmic fluorescence and used nuclear fluorescence as the indicator of reactivity to 3 of their melanomata whereas most other workers have disregarded nuclear fluorescence. The titre of the antibodv detected in the serum has varied from 112 (Muna et al., 1969) to 1/125 (Oettgen et al., 1968) . Other variations are seen in the methods used to fix the cells and even the source of the cells themselves.
It was decided to exclude any sera containing antinuclear factor or smooth muscle antibody, or reacting with adult or foetal fibroblasts, from this study. Most previous authors have not adequately excluded these factors and doubts have been expressed as to the specificity of the reactions described. It was realized that by eliminating these sera, some sera also showing anti-melanoma reactivity might be excluded.
The results indicate that melanoma cells in culture do contain an antigen which reacts with sera from some melanoma patients. However, the cell lines which are most reactive with melanoma sera are also most reactive with normal sera. Similar results are also seen in the reports of Morton et al. (1968) and Rohmsdahl and Cox (1970 of normal sera also react with melanoma cells argues against this new antigen being melanoma specific.
The fact that the proportion of sera positive can be described as 21%O (Table  III) or 55% (Table V) for sera from primary melanomata and either 40/ (Table III) or 81 (Table V) for sera from secondary melanomata, indicates the dangers inherent in analysing data such as these. No serum from a patient with primarv melanoma reacted with all 6 melanoma cell lines, and only 43%' of sera from patients with secondarv melanomata reacted with 3 or more of the cell lines. These findings provide no evidence for the presence of the common antigen in melanoma cells suggested previously by Morton et al. (1968) and Lewis et al. (1969) .
However, it is possible that the tumour specific antigen was lost or greatly diminished at an early stage of the in uitro culture or that relatively non-antigenic cell clones were selected by the tissue culture conditions used. I wish to thank Dr J. H. Little and his colleagues of the Queensland Melanoma Project for obtaining the blood from melanoma patients. I also wish to thank Dr R. L. Doherty and Dr J. H. Pope for their initial guidance and continuing encouragement and advice and Miss Marie Steen and ir P. Bvth for their able technical assistance.
